Cabaletta Bio Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Cabaletta Bio Inc 's ROA in the second quarter of 2026?
Cabaletta Bio Inc recorded a cumulative net loss of $-181 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -95.86%.

However, within the Healthcare sector 720 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4243, from total ROA ranking in the first quarter of 2026 at 4913.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	16.28 %	-8.12 %	-8.5 %	-2.97 %	3.54 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-181	-175	-168	-159	-144
Return On Assets (TTM)	-95.86 %	-97.37 %	-91.51 %	-84.65 %	-76.47 %
CABA's Total Ranking	# 4243	# 4913	# 4311	# 4293	# 4320
Total Assets (TTM) in million	257	148	165	187	221
Seq. Total Assets Change	73.29 %	-10.26 %	-11.54 %	-15.47 %	36.93 %
Seq. Net Income Change	-	-	-	-	-

CABA's 5 Years Annual ROA >> Back to CABA Management Effectiveness >> Compare CABA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 111
Sector	# 721
Overall	# 4195

Return On Assets Statistics
High	Average	Low
-13.05 %	-50 %	-96.46 %
(Jun 30 2020)		(Mar 31 2026)

Financial Statements
Cabaletta Bio Inc 's Assets	$ 257 million	CABA's Balance sheet
Cabaletta Bio Inc 's Income	$ -51 million	Quarterly CABA's Income Statement
CABA's Income by Division		See CABA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-8.5 %	-27.84 %	120.46 %	-10.23 %	10.12 %
Total Assets in million	165	180	250	113	126
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-168	-116	-68	-53	-46
Annual Return On Assets	-101.68 %	-64.22 %	-27.07 %	-46.71 %	-36.64 %

CABA's 5 Years Annual ROA >> Back to CABA Management Effectiveness >> Compare CABA ROA to its Competitors

More Return On Assets Ratios
CABA's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CABA's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CABA's Competitors
Subscribers only: Roa for Cabaletta Bio Inc 's Suppliers
Subscribers only: Return On Assets for CABA's Customers

You may also want to know
CABA's Roi	CABA's Inventory Turnover Ratio	CABA's Growth Rates	CABA's Dividend Comparisons
	CABA's Profitability Ratios	CABA's Asset Turnover Ratio	CABA's Dividend Growth
CABA's Roe	CABA's Valuation Ratios	CABA's Financial Strength Ratios	CABA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-12T06:24:09+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.